Spray drying for generation of a ternary amorphous system of celecoxib, PVP, and meglumine

Pharmaceutical Development and Technology

Volumn 10, Issue 2, 2005, Pages 273-281

  Gupta, Piyush ^a   Bansal, Arvind K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Amorphous; Celecoxib; Optimization; Process parameters; Spray drying

Indexed keywords

CELECOXIB; DRUG ADDITIVE; GELATIN; MEGLUMINE; POVIDONE;

ARTICLE; CRYSTAL STRUCTURE; DRUG CAPSULE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG STORAGE; PRIORITY JOURNAL; SPRAY DRYING;

AIR PRESSURE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DESICCATION; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; MEGLUMINE; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POVIDONE; PYRAZOLES; SOLUBILITY; SOLUTIONS; SOLVENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SULFONAMIDES; TEMPERATURE; X-RAY DIFFRACTION;

EID: 18744397838     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.1081/PDT-200054460     Document Type: Article

References (20)

1. Turnbull, D. Undercooled Alloy Phases: Metallurgical Soc.: Warendale, PA, 1986: 3-22.
2. Zarzycki, J. Glasses and the Vitrecus State; Cambridge University Press: Cambridge, 1990.
3. Hancock, B.C.; Zografi, G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997, 86 (1), 1-12.
4. Guillory, J.K. Generation of polymorphs, hydrates, solvates, and amorphous solids. In Polymorphism in Pharmaceutical Solids; Swarbrick, J., Ed.; Marcel Dekker, Inc.: New York, 1999; 183-226.
5. Nanda, A.R.; Rowlings, C.E.; Barker, N.P.; Sheen, P.-C. Immediate release solid dispersions for oral drug delivery. In Water-Insoluble Drug Formation; Liu, R., Ed.; Interpharm Press: Eagle-wood, 2000; 493-523.
6. Hancock, B.C. Disordered drug delivery: destiny, dynamics and the Deborah number. J. Pharm. Pharmacol. 2002, 54 (6), 737-746,
7. Nielsen, F. Spray drying pharmaceuticals. Manu. Chem. 1982, 53 (7), 38-41.
8. Broadhead, J.; Rouan, S.K.E.; Rhodes, C.T. The spray drying of pharmaceuticals. Drug Dev. Ind. Pharm. 1992, 18 (11 & 12), 1169-1206.
9. Masters, K. Spray Drying Handbook; Longman (UK) & John Wiley & Sons (USA), 1985.
10. Chawla, G.; Gupta, P.; Thilagavathi, R.; Chakraborti, A.K.; Bansal, A.K. Characterization of solid-state forms of celecoxib. Eur. J. Pharm. Sci. 2003, 20 (3), 305-317.
11. Bansal, A.K.; Gupta, P.; Kakumanu, V.K. A Synergistic Pharmaceutical Composition of Celecoxib with Improved Aqueous Solubility. Indian Complete Patent Application No. 685/Del/2002, 2002.
12. United States Pharmacopeia USP 26/National Formulary 21; United States Pharmacopeial Convention, Inc.: Rockville, MD, 2003.
13. Gupta, P.; Kakumanu, V.K.; Bansal, A.K. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective. Pharm. Res. 2004, 21 (10), 1762-1769.
14. Saha, R.N.; Sajeev, C.; Jadhav, P.R.; Patil, S.P.; Srinivasan, N. Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography. J. Pharm. Biomed. Anal. 2002, 28 (3-4), 741-751.
15. Dhabu, P.M.; Akamanchi, K.G. A stability-indicating HPLC method to determine celecoxib in capsule formulations. Drug Dev. Ind. Pharm. 2002, 28 (7), 815-821.
16. Hageman, M.J.; Miyake, P.J.; Stefanski, K.J.; He, X.; Rohrs, B.R.; Mackin, L.A.; Kararli, T.T. Solid-state form of celecoxib having enhanced bioavailability. 2001, WO0141536.
17. Celebrex, 2004. www.celebrex.com (accessed Sept. 2004).
18. Weller, P.J. Meglumine. In Handbook of Pharmaceutical Excipients, 3rd Ed.; Kibbe, A.H., Ed.; American Pharmaceutical Association: Washington, DC, 2000; 332-333.
19. Meglumine. Inactive Ingredients Guide. FDA/Centre for Drug Evaluation and Research, 2004. www.fda.gov/cder/iig (accessed Sept. 2004).
20. The European Agency for the Evaluation of Medicinal Products - CPMP/1361/00, 2000. www.emea.eu.int (accessed Sept. 2004).